SlideShare uma empresa Scribd logo
1 de 145
PATHOGENESIS
      OF
ATHEROSCLEROSIS
History
   This disease has a venerable history,
    having left traces in the arteries of
    Egyptian mummies.
   Apparently uncommon in antiquity,
    atherosclerosis became epidemic as
    populations increasingly survived early
    mortality caused by communicable
    diseases and malnutrition.
   Virchow- viewed atherosclerosis as a
    proliferative disease.

    Rokitansky- believed that atheroma
    derived from healing and resorption of
    thrombi.
   Experiments performed in the early part
    of the 20th century used dietary
    modulation to produce fatty lesions in
    the arteries of rabbits and ultimately
    identified cholesterol as the culprit.

   These observations, followed by the
    characterization of human lipoprotein
    particles at mid-century, promoted the
    concept of insudation of lipids as a cause
    for atherosclerosis
ATHEROSCLEROSIS:
Pathology, Pathogenesis, Complications, Natural History
?
   ? - Affects certain regions of the arterial
    tree preferentially.

   ? - Clinical manifestations occur only at
    certain times.

   ? - Its role in causing narrowing, or
    stenosis, of some vessels and ectasia of
    others.
STRUCTURE OF THE NORMAL ARTERY
   Endothelial cells have a common origin
    but acquire bed-specific characteristics
    during development.
    Arise during embryogenesis from
    regions known as the blood islands,
    located on the embryo's periphery.
   ?- postnatal life-The endothelial
    progenitor cells (EPCs).
   Circulating numbers of EPCs, as assayed in
    vitro, vary among individuals.

   Those with a higher burden of risk factors for
    atherosclerosis have fewer EPCs.

   EPC number may correlate with prognosis in
    atherosclerotic patients.

   More aged individuals may have impaired
    EPC numbers and hence less ability to repair
   Differential expression of endothelial genes
    in various types of blood vessels depends on
    transcriptional regulation by the local
    environment.

    Members of the EPH family of tyrosine
    kinase receptors and their ligands, known as
    ephrins, display heterogeneous expressions in
    arterial versus venous endothelial cells during
    development.
Arterial Smooth Muscle Cells
   These cells contract and relax and thus control
    blood flow through the various arterial beds.
   Abnormal smooth muscle contraction causes
    vasospasm, a complication of atherosclerosis .
   SMCs synthesize the bulk of the complex
    arterial ECM that plays a key role in normal
    vascular homeostasis as well as the formation
    and complication of atherosclerotic lesions.
   These cells also can migrate and proliferate,
    contributing to the formation of intimal
    hyperplastic lesions.

    Death of SMC may promote destabilization
    of atheromatous plaques or favor ectatic
    remodeling and ultimately aneurysm
    formation.
   In the descending aorta and arteries of
    the lower body, the regional mesoderm
    serves as the source of smooth muscle
    precursors.
    In arteries of the upper body, SMCs can
    actually derive from a completely
    different germ layer, neurectoderm
    rather than mesoderm
   SMCs in the coronary arteries derive
    from mesoderm, but in a special
    way[from pro epicardial organ].
   SMCs show molecular heterogeneity
    early during development.
    the promoter of a characteristic smooth
    muscle gene, known as SM22, drives
    gene expression in venous, but not
    arterial.
   Differential dependence on CArG
    elements in the control of SMC gene
    transcription furnishes a molecular basis
    for SMC heterogeneity in different
    arterial beds.
Normal Artery
Response to injury hypothesis
* Injury to the endothelium
   (dysfunctional endothelium)
* Chronic imflammatory response
* Migration of SMC from media to intima
* Proliferation of SMC in intima
• Excess production of ECM

• Enhanced lipid accumulation
Response to injury hypothesis (I)
1. Chronic EC injury (subtle?)
   EC dysfunction
   Increased permeability

   Leukocyte adhesion (via VCAM-1)

   Thrombotic potential
Response to injury hypothesis
                  (II)
2.   Accumulation of LDL (cholesterol)
3.   Oxidation of lesional LDL
4.   Adhesion & migration of blood
     monocytes; transformation into
     macrophages and foam cells
5.   Adhesion of platelets
6.   Release of factors from platelets,
     macrophages and ECs
Response to injury hypothesis
                   (III)
7.    Migration of SMC from media to intima
8.    Proliferation of SMC
9.    ECM production by SMC
10.   Enhanced lipid accumulation
       Intracellular (SMC and macrophages)
       Extracellular
Response to Injury
ATHEROSCLEROSIS INITIATION
Endothelial Dysfunction
Initiation of Fatty Streak
Fatty Streak
Fatty Streak-Aorta
Fibro-fatty Atheroma
Evolution of atheroma
   Smooth Muscle Cell Death During
    Atherogenesis.
   The Arterial Extracellular Matrix.
   Angiogenesis in Plaques.
   Plaque Mineralization
The Focality of Lesion Formation
Lesion progression
COMPLICATIONS OF ATHEROSCLEROSIS

   Plaque Rupture and Thrombosis.

   Thrombosis Caused by Superficial
    Erosion of Plaques.
Plaque Rupture and Thrombosis
Thrombosis Caused by Superficial Erosion of Plaques
Fibrous Plaques   Complicated Lesions
        ?    small atheroma cause most
    myocardial infarctions .
AHA Classification of atherosclerosis



          Fig. 11.7
Novel Invasive Imaging Modalities
OPTICAL COHERENCE TOMOGRAPHY
INTEGRATED BACKSCATTER ANALYSIS
     (“VIRTUAL HISTOLOGY”).
   INTRACORONARY THERMOGRAPHY.

   PALPOGRAPHY.

   COMPUTATIONAL FLOW DYNAMICS.
SPECIAL CASES OF ARTERIOSCLEROSIS

   Restenosis After Arterial Intervention.



   Accelerated Arteriosclerosis Following
    Transplantation.
Restenosis After Arterial Intervention

   After balloon angioplasty, luminal
    narrowing recurs in approximately one-
    third of cases within 6 months.
   These observations renewed interest in
    adventitial inflammation with scar
    formation and wound contraction as a
    mechanism of arterial constriction
    following balloon angioplasty[negative
    remodeling].
Restenosis After Arterial Intervention

   The widespread introduction of stents
    has changed the face of the restenosis
    problem.
   The process of in-stent stenosis, in
    contrast with restenosis after balloon
    angioplasty, depends uniquely on
    intimal thickening.
   Histological analyses reveal that a great
    deal of the volume of the in-stent
    restenotic lesion is made up of
    myxomatous tissue.
   It comprises occasional stellate SMCs
    embedded in a loose and highly
    hydrated extracellular matrix.
   The introduction of stents has reduced the
    clinical impact of restenosis because of the
    very effective increase in luminal diameter
    achieved by this technique.

   stents that elaborate antiproliferative and
    antiinflammatory substances have shown
    great benefit in terms of preventing in-stent
    stenosis.
Accelerated Arteriosclerosis Following
           Transplantation
Aneurysmal Disease
   Atherosclerosis produces not only
    stenoses but also aneurysmal disease .
    Data from the Pathobiological
    Determinants of Atherosclerosis in
    Youth Study (PDAY) show that the
    dorsal surface of the infrarenal
    abdominal aorta has a particular
    predilection .
   Absence of vasa vasorum.

   The relative lack of blood supply to the
    tunica media in this portion of the
    abdominal aorta.

    the lumbar lordosis of the biped human
    may alter the hydrodynamics of blood
    flow in the distal aorta, yielding flow
    disturbances
   Transmural destruction of the arterial architecture occurs in aneurysmal
    disease.

   Many studies have documented overexpression of matrix-degrading
    proteinases, including matrix metalloproteinases in human aortic
    aneurysm specimens.

    Current clinical trials are testing the hypothesis that MMP inhibitors can
    reduce the expansion of aneurysms
Consequences of
Atherosclerosis
Altered Vessel Function

   Vessel change               Consequence
       Plaque narrows              Ischemia, turbulence
        lumen                       Aneurysms, vessel
       Wall weakened                rupture
                                    Narrowing, ischemia,
       Thrombosis                   embolization
                                    Athero-embolization
       Breaking loose of
        plaque
       Loss of elasticity          Increase systolic blood
                                     pressure
Common Consequences of
Atherosclerosis in Specific
         Vessels
Aorta

   Aneurysm
     Pulsatile abdominal mass
     Abdominal pain

     Bleeding

   Atheroembolization
   Narrowing of lumen
       Usually not a problem
Aortic Aneurysm
Carotids and Cerebral
            Circulation
   Atherosclerosis with thrombosis can
    lead to brain infarction
   Red or white
   Coagulative or liquefactive
   Can lead to transient ischemic attacks
    (TIA), if narrowing is aggravated by
    mural thrombus or vasospasm
Celiac and Mesenteric Arteries

   Narrowing primarily at aorta
    bifurcation
   Ischemia uncommon because of
    collateral circulation
   Ischemia can occur if more than 1 artery
    severely affected - ischemic entercolitis
Renal Artery

   Progressive ischemic atrophy of kidney
    leads to gradual kidney failure
    (nephrosclerosis)
   Renal hypertension due to decreased
    perfusion
Iliac and Femoral Arteries

   Aneurysms
   Vessel occlusion by plaque and
    thrombus
     Ischemia of leg muscles, especially during
      exercise (intermittent claudication)
     Ulcers of skin of legs and feet

     Gangrene of feet
Non-Modifiable Risk Factors

   Age
       A dominant influence
       Atherosclerosis begins in the young, but does not
        precipitate organ injury until later in life
   Gender
       Men more prone than women, but by age 60-70
        about equal frequency
   Family History
       Familial cluster of risk factors
       Genetic differences
Modifiable Risk Factors
     (potentially controllable)
   Hyperlipidemia
   Hypertension
   Cigarette smoking
   Diabetes Mellitus
   Elevated Homocysteine
   Factors that affect hemostasis and thrombosis
   Infections: Herpes virus; Chlamydia
    pneumoniae
   Obesity, sedentary lifestyle, stress
NOVEL ATHEROSCLEROTIC RISK FACTORS.
Smoking
   Other than advanced age, smoking is the
    single most important risk factor for
    coronary artery disease.
   Landmark studies in the early 1950s first
    reported strong positive associations
    between cigarette smoke exposure and
    coronary heart disease.
   smoking may enhance oxidation of low-
    density lipoprotein (LDL) cholesterol
    and impair endothelium-dependent
    coronary artery vasodilation.
   Smoking has adverse hemostatic and inflammatory effects,
    including increased levels of CRP, soluble ICAM-1,
    fibrinogen, and homocysteine.

    Cessation of cigarette consumption overwhelmingly
    remains the single most important intervention in
    preventive cardiology.

   Smoking predicts better outcome following various
    reperfusion strategies (the so-called “smoker's paradox”) ---
    smokers are likely to undergo such procedures at a much
    younger age and hence have on average lower comorbidity
Hypertension
   Most epidemiological studies now recognize
    the joint contributions of SBP&DBP to the
    development of CV risk.

   ISH has at least as much importance as DBP
    for the outcomes of total CV &CVA .
   Treatment of systolic hypertension is
    well supported, even in the elderly.
   Isolated systolic hypertension thus
    appears to represent a distinct
    pathophysiological state.
    In ISH elevated blood pressure reflects
    reduced arterial elasticity not necessarily
    associated with increased peripheral
    resistance or an elevation in mean
    arterial pressure.
Hyperlipidemia and Elevated Low-Density
               Lipoprotein Cholesterol
   In the 1850s, the German pathologist Virchow
    recognized in human atheromata “numerous
    plates of cholesterine…which display
    themselves even to the naked eye as
    glistening lamellae.
   Multiple Risk Factor Intervention Trial
    (MRFIT).
    Northwick Park Study and the Prospective
    Cardiovascular Munster (PROCAM) Cohort .
    the Atherosclerosis Risk in Communities
    (ARIC) study.
    REVERSAL trial, which monitored
    intravascular coronary ultrasound,
    PROVE-IT, A-to-Z, and TNT trials, all of
    which support more aggressive use of
    statin therapy for reduction in hard
    clinical endpoints.
Metabolic Syndrome, Insulin
 Resistance, and Diabetes.
Exercise, Weight Loss, and
                 Obesity.
   Physical exercise reduces myocardial oxygen
    demand and increases exercise capacity, both
    of which correlate with lower levels of
    coronary risk.
   The cardioprotective effects of exercise
    include reduced adiposity and diabetes
    incidence, lowered blood pressure, and
    improvement of dyslipidemia, as well as
    vascular inflammation.
   Exercise also enhances endothelial
    dysfunction, insulin sensitivity, and
    endogenous fibrinolysis.
   In the Women's Health Initiative,
    walking briskly for 30 minutes five
    times/week was associated with a 30
    percent reduction in vascular events over
    a 3.5-year follow-up.
   In the Women's Health Study, high BMI
    was more strongly associated with
    adverse cardiovascular biomarkers than
    physical activity
Mental Stress, Depression, and
            Cardiovascular Risk.
   In the INTERHEART study,psychosocial
    stress was found to be associated with
    vascular risk, with a magnitude of effect
    similar to that of the major coronary risk
    factors.
    In the Enhancing Recovery in Coronary Heart
    Disease Patients (ENRICHD) trial,        formal
    psychosocial intervention modestly improved
    measures of clinical depression but did not
    significantly improve event-free survival
High-Sensitivity C-Reactive Protein
   Composed of five 23-kDa subunits, CRP is a
    circulating member of the pentraxin family
    that plays a major role in the human innate
    immune response.

   Although derived primarily from the liver,
    studies have found that cells within human
    coronary arteries, particularly in the
    atherosclerotic intima, can also elaborate CRP.
   hsCRP levels less than 1, 1 to 3, and higher
    than 3 mg/liter should be interpreted as lower,
    moderate, and higher relative vascular risk.
   Values of hsCRP in excess of 8 mg/liter may
    represent an acute-phase response caused by
    an underlying inflammatory disease or
    intercurrent infection and should lead to
    repeat testing in approximately 2 to 3 weeks.
   consistently high values, however, represent
    very high risk of future cardiovascular
    disease.
Fibrinogen and Fibrin D-Dimer
   fibrinogen associates positively with age,
    obesity, smoking, diabetes, and LDL
    cholesterol level, and inversely with
    HDL cholesterol level, alcohol use,
    physical activity, and exercise level.

   Fibrinogen, like CRP, is an acute-phase
    reactant and increases during
    inflammatory responses.
   Despite the consistency of these data,
    fibrinogen evaluation has found limited
    use in clinical practice because of
    suboptimal assay standardization and
    consistency across reference laboratories
    remains poor.
Lipoprotein(a)
   Lipoprotein(a) (Lp[a]) consists of an LDL
    particle with its apolipoprotein B-100 (apo B-
    100) component linked by a disulfide bridge
    to apolipoprotein(a) (apo[a]).

   The close homology between Lp(a) and
    plasminogen has raised the possibility that
    this lipoprotein may inhibit endogenous
    fibrinolysis.
   Many but not all prospective cohort studies
    have supported a role for Lp(a) as a
    determinant of vascular risk.
   Standardization of commercial Lp(a) assays
    remains problematic and inaccuracy of
    commercial Lp(a) assays has resulted from
    the use of techniques sensitive to apo(a)
    size.
   Women's Health Study have found that
    extremely high levels of Lp(a) (greater
    than the 90th percentile, or higher than
    65.6 mg/liter) are indeed associated with
    increased cardiovascular risk,
    independent of other traditional risk
    factors.
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3
Atherosclerosis3

Mais conteúdo relacionado

Mais procurados

Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathyHypertrophic cardiomyopathy
Hypertrophic cardiomyopathy
Fuad Farooq
 
Diseases of the aorta
Diseases of the aortaDiseases of the aorta
Diseases of the aorta
Fuad Farooq
 

Mais procurados (20)

Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathyHypertrophic cardiomyopathy
Hypertrophic cardiomyopathy
 
Pericardial effusion
Pericardial effusionPericardial effusion
Pericardial effusion
 
Coronary artery anatomy
Coronary artery anatomyCoronary artery anatomy
Coronary artery anatomy
 
INFARCTION
INFARCTION INFARCTION
INFARCTION
 
Tricuspid valve stenosis
Tricuspid valve stenosisTricuspid valve stenosis
Tricuspid valve stenosis
 
dialated cardiomyopathies
dialated cardiomyopathiesdialated cardiomyopathies
dialated cardiomyopathies
 
Valvular heart disease
Valvular heart diseaseValvular heart disease
Valvular heart disease
 
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathyHypertrophic cardiomyopathy
Hypertrophic cardiomyopathy
 
Renal Hypertension
Renal HypertensionRenal Hypertension
Renal Hypertension
 
Thrombosis
ThrombosisThrombosis
Thrombosis
 
Cardiac tumors
Cardiac tumorsCardiac tumors
Cardiac tumors
 
Heart failure
Heart failureHeart failure
Heart failure
 
Coronary angiography
Coronary angiographyCoronary angiography
Coronary angiography
 
Aneurysms
AneurysmsAneurysms
Aneurysms
 
Blood pumps
Blood pumpsBlood pumps
Blood pumps
 
DVT
DVTDVT
DVT
 
Approach to patient with Dilated Cardiomyopathy
Approach to patient with Dilated CardiomyopathyApproach to patient with Dilated Cardiomyopathy
Approach to patient with Dilated Cardiomyopathy
 
Diseases of the aorta
Diseases of the aortaDiseases of the aorta
Diseases of the aorta
 
Lecture 10 valvular heart disease - Pathology
Lecture 10 valvular heart disease - Pathology Lecture 10 valvular heart disease - Pathology
Lecture 10 valvular heart disease - Pathology
 
Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 

Destaque

PATHOLOGY - Arteriosclerosis
PATHOLOGY - ArteriosclerosisPATHOLOGY - Arteriosclerosis
PATHOLOGY - Arteriosclerosis
Nian Baring
 

Destaque (20)

Atherosclerosis - Pathogenesis
Atherosclerosis - PathogenesisAtherosclerosis - Pathogenesis
Atherosclerosis - Pathogenesis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Atherosclerosis ppt
Atherosclerosis pptAtherosclerosis ppt
Atherosclerosis ppt
 
8. atherosclerosis
8. atherosclerosis8. atherosclerosis
8. atherosclerosis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Atherosclerosis 3
Atherosclerosis 3Atherosclerosis 3
Atherosclerosis 3
 
The vascular biology of atherosclerosis
The vascular biology of atherosclerosisThe vascular biology of atherosclerosis
The vascular biology of atherosclerosis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
PATHOLOGY - Arteriosclerosis
PATHOLOGY - ArteriosclerosisPATHOLOGY - Arteriosclerosis
PATHOLOGY - Arteriosclerosis
 
Aterosclerosis
AterosclerosisAterosclerosis
Aterosclerosis
 
ADA-EASD statement: Management of Hyperglycemia in Type 2 Diabetes
ADA-EASD statement: Management of Hyperglycemia in Type 2 DiabetesADA-EASD statement: Management of Hyperglycemia in Type 2 Diabetes
ADA-EASD statement: Management of Hyperglycemia in Type 2 Diabetes
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Sruthi
SruthiSruthi
Sruthi
 
Adenocarcinoma Prognosis
Adenocarcinoma PrognosisAdenocarcinoma Prognosis
Adenocarcinoma Prognosis
 
Recent developments in the treatment of atherosclerosis
Recent developments in the treatment of  atherosclerosisRecent developments in the treatment of  atherosclerosis
Recent developments in the treatment of atherosclerosis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Arteriosclerosis 6
Arteriosclerosis 6Arteriosclerosis 6
Arteriosclerosis 6
 
Artherosclerosis
ArtherosclerosisArtherosclerosis
Artherosclerosis
 

Semelhante a Atherosclerosis3

Diseases of vessels
Diseases of vesselsDiseases of vessels
Diseases of vessels
adolescent4u
 
Cardiac pathology
Cardiac pathologyCardiac pathology
Cardiac pathology
Springer
 
3 Disturbabce of blood circulation 2021.pdf
3 Disturbabce of blood circulation 2021.pdf3 Disturbabce of blood circulation 2021.pdf
3 Disturbabce of blood circulation 2021.pdf
vanastaciost
 
Blood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptx
Blood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptxBlood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptx
Blood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptx
Sam Edeson
 
Carotid endarterectomy
Carotid endarterectomyCarotid endarterectomy
Carotid endarterectomy
Liew Boon Seng
 
15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt
15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt
15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt
Learta Asani
 

Semelhante a Atherosclerosis3 (20)

Lecture 16 cardiovascular system
Lecture 16 cardiovascular systemLecture 16 cardiovascular system
Lecture 16 cardiovascular system
 
Diseases of vessels
Diseases of vesselsDiseases of vessels
Diseases of vessels
 
Avascular necrosis
Avascular necrosisAvascular necrosis
Avascular necrosis
 
Cardiac pathology
Cardiac pathologyCardiac pathology
Cardiac pathology
 
5. Blood Vessels.pptx
5. Blood Vessels.pptx5. Blood Vessels.pptx
5. Blood Vessels.pptx
 
Atherosclerosis by neha
Atherosclerosis by nehaAtherosclerosis by neha
Atherosclerosis by neha
 
Vulnerable plaque
Vulnerable plaqueVulnerable plaque
Vulnerable plaque
 
3 Disturbabce of blood circulation 2021.pdf
3 Disturbabce of blood circulation 2021.pdf3 Disturbabce of blood circulation 2021.pdf
3 Disturbabce of blood circulation 2021.pdf
 
атеросклероз лекция.pptx
атеросклероз лекция.pptxатеросклероз лекция.pptx
атеросклероз лекция.pptx
 
Blood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptx
Blood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptxBlood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptx
Blood coagulation, Embolism, Ischaemia and Infarction [Autosaved].pptx
 
THE VASCULITIS SYNDROME
THE VASCULITIS SYNDROMETHE VASCULITIS SYNDROME
THE VASCULITIS SYNDROME
 
THE VASCULITIS SYNDROME
THE VASCULITIS SYNDROMETHE VASCULITIS SYNDROME
THE VASCULITIS SYNDROME
 
Carotid endarterectomy
Carotid endarterectomyCarotid endarterectomy
Carotid endarterectomy
 
Vessel Wall Biology & Atherosclerosis.pptx
Vessel Wall Biology & Atherosclerosis.pptxVessel Wall Biology & Atherosclerosis.pptx
Vessel Wall Biology & Atherosclerosis.pptx
 
CVS Pathology 5 Thromboembolism 2019, sufia husain
CVS Pathology 5 Thromboembolism 2019, sufia husainCVS Pathology 5 Thromboembolism 2019, sufia husain
CVS Pathology 5 Thromboembolism 2019, sufia husain
 
Arteriosclerosis and venous disease
Arteriosclerosis and venous diseaseArteriosclerosis and venous disease
Arteriosclerosis and venous disease
 
Arteriosclerosis 5 5-2014 lect 3
Arteriosclerosis 5 5-2014 lect 3Arteriosclerosis 5 5-2014 lect 3
Arteriosclerosis 5 5-2014 lect 3
 
15-HEMODYNAMIC DISORDERS.ppt
15-HEMODYNAMIC DISORDERS.ppt15-HEMODYNAMIC DISORDERS.ppt
15-HEMODYNAMIC DISORDERS.ppt
 
15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt
15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt
15-pathology of hemodynamicsHEMODYNAMIC DISORDERS.ppt
 
02 vascular pathology
02 vascular pathology02 vascular pathology
02 vascular pathology
 

Mais de Gopi Krishna Rayidi

Mais de Gopi Krishna Rayidi (15)

Bifurcation stenting strategies.ppt
Bifurcation stenting strategies.pptBifurcation stenting strategies.ppt
Bifurcation stenting strategies.ppt
 
heart failure device therapy
heart failure device therapyheart failure device therapy
heart failure device therapy
 
saphenou vein graft interventions
saphenou vein graft interventionssaphenou vein graft interventions
saphenou vein graft interventions
 
cardiac tumors
cardiac  tumorscardiac  tumors
cardiac tumors
 
carotid angioplasty
carotid angioplastycarotid angioplasty
carotid angioplasty
 
takayasu arteritis
 takayasu arteritis takayasu arteritis
takayasu arteritis
 
Management of diabetes in heart disease
Management of diabetes  in heart diseaseManagement of diabetes  in heart disease
Management of diabetes in heart disease
 
transposition of great arteries
transposition of great arteriestransposition of great arteries
transposition of great arteries
 
saphenous venous graft interventions
saphenous  venous graft interventionssaphenous  venous graft interventions
saphenous venous graft interventions
 
Carotid angioplasty
Carotid angioplastyCarotid angioplasty
Carotid angioplasty
 
Cardiac embryology seminar copy
Cardiac embryology seminar   copyCardiac embryology seminar   copy
Cardiac embryology seminar copy
 
Cardiac cycle ppt (2)
Cardiac cycle ppt (2)Cardiac cycle ppt (2)
Cardiac cycle ppt (2)
 
atio ventricular septal defects
atio ventricular septal defectsatio ventricular septal defects
atio ventricular septal defects
 
Takayasu arteritis.fin al
Takayasu arteritis.fin alTakayasu arteritis.fin al
Takayasu arteritis.fin al
 
Anatomy of cardiac structures & conducting system in
Anatomy of cardiac structures & conducting system inAnatomy of cardiac structures & conducting system in
Anatomy of cardiac structures & conducting system in
 

Atherosclerosis3

  • 1. PATHOGENESIS OF ATHEROSCLEROSIS
  • 2. History  This disease has a venerable history, having left traces in the arteries of Egyptian mummies.  Apparently uncommon in antiquity, atherosclerosis became epidemic as populations increasingly survived early mortality caused by communicable diseases and malnutrition.
  • 3. Virchow- viewed atherosclerosis as a proliferative disease.  Rokitansky- believed that atheroma derived from healing and resorption of thrombi.
  • 4. Experiments performed in the early part of the 20th century used dietary modulation to produce fatty lesions in the arteries of rabbits and ultimately identified cholesterol as the culprit.  These observations, followed by the characterization of human lipoprotein particles at mid-century, promoted the concept of insudation of lipids as a cause for atherosclerosis
  • 6. ?  ? - Affects certain regions of the arterial tree preferentially.  ? - Clinical manifestations occur only at certain times.  ? - Its role in causing narrowing, or stenosis, of some vessels and ectasia of others.
  • 7. STRUCTURE OF THE NORMAL ARTERY
  • 8. Endothelial cells have a common origin but acquire bed-specific characteristics during development.  Arise during embryogenesis from regions known as the blood islands, located on the embryo's periphery.  ?- postnatal life-The endothelial progenitor cells (EPCs).
  • 9. Circulating numbers of EPCs, as assayed in vitro, vary among individuals.  Those with a higher burden of risk factors for atherosclerosis have fewer EPCs.  EPC number may correlate with prognosis in atherosclerotic patients.  More aged individuals may have impaired EPC numbers and hence less ability to repair
  • 10. Differential expression of endothelial genes in various types of blood vessels depends on transcriptional regulation by the local environment.  Members of the EPH family of tyrosine kinase receptors and their ligands, known as ephrins, display heterogeneous expressions in arterial versus venous endothelial cells during development.
  • 11. Arterial Smooth Muscle Cells  These cells contract and relax and thus control blood flow through the various arterial beds.  Abnormal smooth muscle contraction causes vasospasm, a complication of atherosclerosis .  SMCs synthesize the bulk of the complex arterial ECM that plays a key role in normal vascular homeostasis as well as the formation and complication of atherosclerotic lesions.
  • 12. These cells also can migrate and proliferate, contributing to the formation of intimal hyperplastic lesions.  Death of SMC may promote destabilization of atheromatous plaques or favor ectatic remodeling and ultimately aneurysm formation.
  • 13. In the descending aorta and arteries of the lower body, the regional mesoderm serves as the source of smooth muscle precursors.  In arteries of the upper body, SMCs can actually derive from a completely different germ layer, neurectoderm rather than mesoderm
  • 14. SMCs in the coronary arteries derive from mesoderm, but in a special way[from pro epicardial organ].  SMCs show molecular heterogeneity early during development.  the promoter of a characteristic smooth muscle gene, known as SM22, drives gene expression in venous, but not arterial.
  • 15. Differential dependence on CArG elements in the control of SMC gene transcription furnishes a molecular basis for SMC heterogeneity in different arterial beds.
  • 16.
  • 18. Response to injury hypothesis * Injury to the endothelium (dysfunctional endothelium) * Chronic imflammatory response * Migration of SMC from media to intima * Proliferation of SMC in intima • Excess production of ECM • Enhanced lipid accumulation
  • 19. Response to injury hypothesis (I) 1. Chronic EC injury (subtle?)  EC dysfunction  Increased permeability  Leukocyte adhesion (via VCAM-1)  Thrombotic potential
  • 20. Response to injury hypothesis (II) 2. Accumulation of LDL (cholesterol) 3. Oxidation of lesional LDL 4. Adhesion & migration of blood monocytes; transformation into macrophages and foam cells 5. Adhesion of platelets 6. Release of factors from platelets, macrophages and ECs
  • 21. Response to injury hypothesis (III) 7. Migration of SMC from media to intima 8. Proliferation of SMC 9. ECM production by SMC 10. Enhanced lipid accumulation Intracellular (SMC and macrophages) Extracellular
  • 25.
  • 30.
  • 31.
  • 33. Smooth Muscle Cell Death During Atherogenesis.  The Arterial Extracellular Matrix.  Angiogenesis in Plaques.  Plaque Mineralization
  • 34.
  • 35. The Focality of Lesion Formation
  • 37. COMPLICATIONS OF ATHEROSCLEROSIS  Plaque Rupture and Thrombosis.  Thrombosis Caused by Superficial Erosion of Plaques.
  • 38.
  • 39. Plaque Rupture and Thrombosis
  • 40. Thrombosis Caused by Superficial Erosion of Plaques
  • 41.
  • 42. Fibrous Plaques Complicated Lesions
  • 43. ? small atheroma cause most myocardial infarctions .
  • 44.
  • 45. AHA Classification of atherosclerosis Fig. 11.7
  • 46.
  • 47.
  • 48.
  • 51. INTEGRATED BACKSCATTER ANALYSIS (“VIRTUAL HISTOLOGY”).
  • 52. INTRACORONARY THERMOGRAPHY.  PALPOGRAPHY.  COMPUTATIONAL FLOW DYNAMICS.
  • 53.
  • 54. SPECIAL CASES OF ARTERIOSCLEROSIS  Restenosis After Arterial Intervention.  Accelerated Arteriosclerosis Following Transplantation.
  • 55. Restenosis After Arterial Intervention  After balloon angioplasty, luminal narrowing recurs in approximately one- third of cases within 6 months.  These observations renewed interest in adventitial inflammation with scar formation and wound contraction as a mechanism of arterial constriction following balloon angioplasty[negative remodeling].
  • 56. Restenosis After Arterial Intervention  The widespread introduction of stents has changed the face of the restenosis problem.  The process of in-stent stenosis, in contrast with restenosis after balloon angioplasty, depends uniquely on intimal thickening.
  • 57. Histological analyses reveal that a great deal of the volume of the in-stent restenotic lesion is made up of myxomatous tissue.  It comprises occasional stellate SMCs embedded in a loose and highly hydrated extracellular matrix.
  • 58. The introduction of stents has reduced the clinical impact of restenosis because of the very effective increase in luminal diameter achieved by this technique.  stents that elaborate antiproliferative and antiinflammatory substances have shown great benefit in terms of preventing in-stent stenosis.
  • 60.
  • 61. Aneurysmal Disease  Atherosclerosis produces not only stenoses but also aneurysmal disease .  Data from the Pathobiological Determinants of Atherosclerosis in Youth Study (PDAY) show that the dorsal surface of the infrarenal abdominal aorta has a particular predilection .
  • 62. Absence of vasa vasorum.  The relative lack of blood supply to the tunica media in this portion of the abdominal aorta.  the lumbar lordosis of the biped human may alter the hydrodynamics of blood flow in the distal aorta, yielding flow disturbances
  • 63. Transmural destruction of the arterial architecture occurs in aneurysmal disease.  Many studies have documented overexpression of matrix-degrading proteinases, including matrix metalloproteinases in human aortic aneurysm specimens.  Current clinical trials are testing the hypothesis that MMP inhibitors can reduce the expansion of aneurysms
  • 65.
  • 66. Altered Vessel Function  Vessel change  Consequence  Plaque narrows  Ischemia, turbulence lumen  Aneurysms, vessel  Wall weakened rupture  Narrowing, ischemia,  Thrombosis embolization  Athero-embolization  Breaking loose of plaque  Loss of elasticity  Increase systolic blood pressure
  • 68. Aorta  Aneurysm  Pulsatile abdominal mass  Abdominal pain  Bleeding  Atheroembolization  Narrowing of lumen  Usually not a problem
  • 70. Carotids and Cerebral Circulation  Atherosclerosis with thrombosis can lead to brain infarction  Red or white  Coagulative or liquefactive  Can lead to transient ischemic attacks (TIA), if narrowing is aggravated by mural thrombus or vasospasm
  • 71. Celiac and Mesenteric Arteries  Narrowing primarily at aorta bifurcation  Ischemia uncommon because of collateral circulation  Ischemia can occur if more than 1 artery severely affected - ischemic entercolitis
  • 72. Renal Artery  Progressive ischemic atrophy of kidney leads to gradual kidney failure (nephrosclerosis)  Renal hypertension due to decreased perfusion
  • 73. Iliac and Femoral Arteries  Aneurysms  Vessel occlusion by plaque and thrombus  Ischemia of leg muscles, especially during exercise (intermittent claudication)  Ulcers of skin of legs and feet  Gangrene of feet
  • 74. Non-Modifiable Risk Factors  Age  A dominant influence  Atherosclerosis begins in the young, but does not precipitate organ injury until later in life  Gender  Men more prone than women, but by age 60-70 about equal frequency  Family History  Familial cluster of risk factors  Genetic differences
  • 75. Modifiable Risk Factors (potentially controllable)  Hyperlipidemia  Hypertension  Cigarette smoking  Diabetes Mellitus  Elevated Homocysteine  Factors that affect hemostasis and thrombosis  Infections: Herpes virus; Chlamydia pneumoniae  Obesity, sedentary lifestyle, stress
  • 77. Smoking  Other than advanced age, smoking is the single most important risk factor for coronary artery disease.  Landmark studies in the early 1950s first reported strong positive associations between cigarette smoke exposure and coronary heart disease.  smoking may enhance oxidation of low- density lipoprotein (LDL) cholesterol and impair endothelium-dependent coronary artery vasodilation.
  • 78. Smoking has adverse hemostatic and inflammatory effects, including increased levels of CRP, soluble ICAM-1, fibrinogen, and homocysteine.  Cessation of cigarette consumption overwhelmingly remains the single most important intervention in preventive cardiology.  Smoking predicts better outcome following various reperfusion strategies (the so-called “smoker's paradox”) --- smokers are likely to undergo such procedures at a much younger age and hence have on average lower comorbidity
  • 79. Hypertension  Most epidemiological studies now recognize the joint contributions of SBP&DBP to the development of CV risk.  ISH has at least as much importance as DBP for the outcomes of total CV &CVA .
  • 80. Treatment of systolic hypertension is well supported, even in the elderly.  Isolated systolic hypertension thus appears to represent a distinct pathophysiological state.  In ISH elevated blood pressure reflects reduced arterial elasticity not necessarily associated with increased peripheral resistance or an elevation in mean arterial pressure.
  • 81. Hyperlipidemia and Elevated Low-Density Lipoprotein Cholesterol  In the 1850s, the German pathologist Virchow recognized in human atheromata “numerous plates of cholesterine…which display themselves even to the naked eye as glistening lamellae.  Multiple Risk Factor Intervention Trial (MRFIT).  Northwick Park Study and the Prospective Cardiovascular Munster (PROCAM) Cohort .  the Atherosclerosis Risk in Communities (ARIC) study.
  • 82. REVERSAL trial, which monitored intravascular coronary ultrasound, PROVE-IT, A-to-Z, and TNT trials, all of which support more aggressive use of statin therapy for reduction in hard clinical endpoints.
  • 83.
  • 84.
  • 85. Metabolic Syndrome, Insulin Resistance, and Diabetes.
  • 86. Exercise, Weight Loss, and Obesity.  Physical exercise reduces myocardial oxygen demand and increases exercise capacity, both of which correlate with lower levels of coronary risk.  The cardioprotective effects of exercise include reduced adiposity and diabetes incidence, lowered blood pressure, and improvement of dyslipidemia, as well as vascular inflammation.
  • 87. Exercise also enhances endothelial dysfunction, insulin sensitivity, and endogenous fibrinolysis.  In the Women's Health Initiative, walking briskly for 30 minutes five times/week was associated with a 30 percent reduction in vascular events over a 3.5-year follow-up.  In the Women's Health Study, high BMI was more strongly associated with adverse cardiovascular biomarkers than physical activity
  • 88. Mental Stress, Depression, and Cardiovascular Risk.  In the INTERHEART study,psychosocial stress was found to be associated with vascular risk, with a magnitude of effect similar to that of the major coronary risk factors.  In the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) trial, formal psychosocial intervention modestly improved measures of clinical depression but did not significantly improve event-free survival
  • 89.
  • 90. High-Sensitivity C-Reactive Protein  Composed of five 23-kDa subunits, CRP is a circulating member of the pentraxin family that plays a major role in the human innate immune response.  Although derived primarily from the liver, studies have found that cells within human coronary arteries, particularly in the atherosclerotic intima, can also elaborate CRP.
  • 91.
  • 92. hsCRP levels less than 1, 1 to 3, and higher than 3 mg/liter should be interpreted as lower, moderate, and higher relative vascular risk.  Values of hsCRP in excess of 8 mg/liter may represent an acute-phase response caused by an underlying inflammatory disease or intercurrent infection and should lead to repeat testing in approximately 2 to 3 weeks.  consistently high values, however, represent very high risk of future cardiovascular disease.
  • 93. Fibrinogen and Fibrin D-Dimer  fibrinogen associates positively with age, obesity, smoking, diabetes, and LDL cholesterol level, and inversely with HDL cholesterol level, alcohol use, physical activity, and exercise level.  Fibrinogen, like CRP, is an acute-phase reactant and increases during inflammatory responses.
  • 94.
  • 95. Despite the consistency of these data, fibrinogen evaluation has found limited use in clinical practice because of suboptimal assay standardization and consistency across reference laboratories remains poor.
  • 96. Lipoprotein(a)  Lipoprotein(a) (Lp[a]) consists of an LDL particle with its apolipoprotein B-100 (apo B- 100) component linked by a disulfide bridge to apolipoprotein(a) (apo[a]).  The close homology between Lp(a) and plasminogen has raised the possibility that this lipoprotein may inhibit endogenous fibrinolysis.
  • 97. Many but not all prospective cohort studies have supported a role for Lp(a) as a determinant of vascular risk.  Standardization of commercial Lp(a) assays remains problematic and inaccuracy of commercial Lp(a) assays has resulted from the use of techniques sensitive to apo(a) size.
  • 98. Women's Health Study have found that extremely high levels of Lp(a) (greater than the 90th percentile, or higher than 65.6 mg/liter) are indeed associated with increased cardiovascular risk, independent of other traditional risk factors.